Treatment of Right-Sided Staphylococcus Aureus Endocarditis in Intravenous Drug Users With Ciprofloxacin and Rifampicin

Dworkin, Ronald J.; Sande, Merle A.; Lee, B.L.; Chambers, Henry F.

doi:10.1016/s0140-6736(89)91083-0

Cited by 186 publications

(102 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They both have excellent oral bioavailability and safety, allowing them to be used for prolonged courses of therapy. The quinolone-rifampin combinations that have been studied include ciprofloxacin, perfloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin (18,73,74,106,117,137,279).…”

Section: Staphylococcimentioning

confidence: 99%

“…The reasons for considering rifampin combination therapy for native valve endocarditis (NVE) are (i) that it is highly active against S. aureus, (ii) that it has good tissue and vegetation penetration, and (iii) that oral therapy can be used to discharge intravenous drug users early from hospital (57,74,237). However, what has not been defined are the timing of the addition of rifampin to the other antibiotic in relation to bacteremia, the appropriate dose and interval of rifampin needed, how long therapy should be maintained once initiated, and patient adherence to therapy if being managed as an outpatient (57,74,163,227 Table 4).…”

Section: Staphylococcimentioning

confidence: 99%

“…Maor et al retrospectively studied 27 patients with hVISA bacteremia compared to 223 patients with MRSA bacteremia. Those authors found that patients with hVISA bacteremia were more likely to have prolonged bacter- (74). All 10 patients that completed therapy had bacteria cleared from blood cultures at 4 weeks; however, 4 patients did not complete therapy due to nonadherence, a concern for outpatient endocarditis therapy (74).…”

Section: Staphylococcimentioning

confidence: 99%

See 2 more Smart Citations

Rifampin Combination Therapy for Nonmycobacterial Infections

2010

View full text Add to dashboard Cite

SUMMARY The increasing emergence of antimicrobial-resistant organisms, especially methicillin-resistant Staphylococcus aureus (MRSA), has resulted in the increased use of rifampin combination therapy. The data supporting rifampin combination therapy in nonmycobacterial infections are limited by a lack of significantly controlled clinical studies. Therefore, its current use is based upon in vitro or in vivo data or retrospective case series, all with major limitations. A prominent observation from this review is that rifampin combination therapy appears to have improved treatment outcomes in cases in which there is a low organism burden, such as biofilm infections, but is less effective when effective surgery to obtain source control is not performed. The clinical data support rifampin combination therapy for the treatment of prosthetic joint infections due to methicillin-sensitive S. aureus (MSSA) after extensive debridement and for the treatment of prosthetic heart valve infections due to coagulase-negative staphylococci. Importantly, rifampin-vancomycin combination therapy has not shown any benefit over vancomycin monotherapy against MRSA infections either clinically or experimentally. Rifampin combination therapy with daptomycin, fusidic acid, and linezolid needs further exploration for these severe MRSA infections. Lastly, an assessment of the risk-benefits is needed before the addition of rifampin to other antimicrobials is considered to avoid drug interactions or other drug toxicities.

show abstract

Section: Staphylococcimentioning

confidence: 99%

Section: Staphylococcimentioning

confidence: 99%

Section: Staphylococcimentioning

confidence: 99%

See 1 more Smart Citation

Rifampin Combination Therapy for Nonmycobacterial Infections

2010

View full text Add to dashboard Cite

show abstract

“…Rifampin has excellent efficacy in the treatment of ODRIs (these infections may be cured), a property that correlates with its ability to eradicate adherent and nongrowing staphylococci. Combination therapy with ciprofloxacin and rifampin has recently been used effectively as oral treatment of S. aureus right-sided endocarditis [10]. Rifampin has good bioavailability, a relatively long half-life (2.5 hours), and excellent activity against staphylococci.…”

mentioning

confidence: 99%

Antimicrobial Treatment of Orthopedic Implant-related Infections with Rifampin Combinations

Widmer¹,

Gaêchter²,

Ochsner³

et al. 1992

Clinical Infectious Diseases

235

144

View full text Add to dashboard Cite

The purpose of this prospective clinical study is to evaluate the role of combination chemotherapy with rifampin in the treatment of orthopedic device-related infections in which the implant could not be removed. Eleven patients with orthopedic implant-related infections due to staphylococci or streptococci were treated with the implant in situ. Each antimicrobial regimen included rifampin in combination with a 19-lactam antibiotic or ciprofloxacin. The median duration of treatment with rifampin was 86 days (range, 15-336 days) with a median follow-up of >24 months after cessation of therapy. Treatment was successful for 82% of patients. Failures were associated with documented inappropriate treatment. These preliminary clinical data are supported by data from in vitro studies and animal experiments. Combination therapy with rifampin, in particular rifampin and a quinolone, should be considered for patients with orthopedic implant-related infections if the implant cannot be removed.Long-term intravenous therapy combined with a one-or two-stage replacement is frequently necessary for controlling orthopedic device-related infection (ODRI) [1]. New antimicrobial regimens may cure infections that were previously considered as necessitating removal of the device [2]. We previously observed in an animal model that even short-term treatment with rifampin can sterilize implant-related infections due to Staphylococcus epidermidis and Staphylococcus aureus [3][4][5]. The present trial was designed as a pilot study for evaluating whether a rifampin-containing regimen could cure ODRIs rather than only suppress the clinical symptoms. We applied such a regimen to 11 patients who had ODRIs and from whom the device could not be removed.We prospectively observed 11 patients (five women and six men) with ODRIs due to gram-positive cocci who were consulted by physicians from the Division of Infectious Diseases (A

show abstract

“…for 1 week followed by 750 mg q 12 h orally for three further weeks, with rifampin 300 mg q 12 h orally. This was successfully given to ten patients with rightsided S. aureus endocarditis' 11 '. Ciprofloxacin and related quinolones, however, are increasingly reported as being inactive on staphylococci.…”

Section: Short Regimensmentioning

confidence: 99%

Medical treatment of staphylococcal infective endocarditis

Billé

1995

European Heart Journal

View full text Add to dashboard Cite

Treatment of Right-Sided Staphylococcus Aureus Endocarditis in Intravenous Drug Users With Ciprofloxacin and Rifampicin

Cited by 186 publications

References 9 publications

Rifampin Combination Therapy for Nonmycobacterial Infections

Rifampin Combination Therapy for Nonmycobacterial Infections

Antimicrobial Treatment of Orthopedic Implant-related Infections with Rifampin Combinations

Medical treatment of staphylococcal infective endocarditis

Contact Info

Product

Resources

About